BioMed Realty Trust Upgraded to Outperform at Cowen and Company (BMR)
BioMed Realty Trust (NYSE:BMR) was upgraded by investment analysts at Cowen and Company from a “market perform” rating to an “outperform” rating in a note issued to investors on Thursday, AnalystRatings.Net reports. The firm currently has a $20.00 price target on the stock, down from their previous price target of $22.00. Cowen and Company’s price target would suggest a potential upside of 6.61% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Morgan Stanley upgraded shares of BioMed Realty Trust (NYSE:BMR) from an “equal weight” rating to an “overweight” rating in a research note to investors on Tuesday. They now have a $23.00 price target on the stock. Separately, analysts at TheStreet downgraded shares of BioMed Realty Trust (NYSE:BMR) to a “hold” rating in a research note to investors on Monday. Finally, analysts at Jefferies Group cut their price target on shares of BioMed Realty Trust (NYSE:BMR) from $25.00 to $24.00 in a research note to investors on Wednesday, July 24th. They now have a “buy” rating on the stock.
Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $22.64.
BioMed Realty Trust (NYSE:BMR) traded down 0.74% during mid-day trading on Thursday, hitting $18.76. The stock had a trading volume of 1,480,994 shares. BioMed Realty Trust has a 52 week low of $17.90 and a 52 week high of $23.13. The stock’s 50-day moving average is $19.29 and its 200-day moving average is $20.95. The company has a market cap of $3.503 billion and a price-to-earnings ratio of 108.00.
BioMed Realty Trust (NYSE:BMR) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.37 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.39 by $0.02. The company had revenue of $159.64 million for the quarter, compared to the consensus estimate of $143.47 million. During the same quarter in the prior year, the company posted $0.32 earnings per share. The company’s quarterly revenue was up 27.9% on a year-over-year basis. On average, analysts predict that BioMed Realty Trust will post $1.48 earnings per share for the current fiscal year.
BioMed Realty Trust, Inc operates as a real estate investment trust (NYSE:BMR), and the general partner of BioMed Realty, L.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.